Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
Hang Chu, San Mateo, CA (US); Ana Z. Gonzalez Buenrostro, San Mateo, CA (US); Hongyan Guo, San Mateo, CA (US); Xiaochun Han, San Jose, CA (US); Lan Jiang, Foster City, CA (US); Jiayao Li, Foster City, CA (US); Michael L. Mitchell, Castro Valley, CA (US); Hyung-Jung Pyun, Fremont, CA (US); Scott D. Schroeder, Union City, CA (US); Gregg M. Schwarzwalder, Redwood City, CA (US); Nathan D. Shapiro, Belmont, CA (US); Devleena M. Shivakumar, Menlo Park, CA (US); Qiaoyin Wu, Foster City, CA (US); Hong Yang, Fremont, CA (US); and Jennifer R. Zhang, Union City, CA (US)
Assigned to Gilead Sciences, Inc., Foster City, CA (US)
Filed by Gilead Sciences, Inc., Foster City, CA (US)
Filed on Oct. 28, 2022, as Appl. No. 18/050,650.
Application 18/050,650 is a continuation of application No. 17/361,758, filed on Jun. 29, 2021, granted, now 11,548,902.
Application 17/361,758 is a continuation of application No. 16/825,142, filed on Mar. 20, 2020, granted, now 11,084,832, issued on Aug. 10, 2021.
Claims priority of provisional application 62/948,697, filed on Dec. 16, 2019.
Claims priority of provisional application 62/822,703, filed on Mar. 22, 2019.
Prior Publication US 2023/0203061 A1, Jun. 29, 2023
